checkAd

Lexicon Pharmaceuticals Aktie WKN: 936717 ISIN: US5288721047 Symbol: LXRX Typ: Aktie

eröffnet am 13.03.15 09:18:58 von
neuester Beitrag 12.08.22 23:01:32 von


Beitrag zu dieser Diskussion schreiben

  • 1
  • 11

Begriffe und/oder Benutzer

 

Top-Postings

 Ja Nein
    Avatar
    12.08.22 23:01:32
    Beitrag Nr. 107 ()
    Antwort auf Beitrag Nr.: 72.184.752 von Charly_2 am 12.08.22 16:33:51Analyst projects a $22.1B market opportunity for Sotagliflozin, Piper Sandler sees “blockbuster potential” for key assets.

    The analyst Yasmeen Rahimi points to the company’s oral drug candidate Sotagliflozin which has undergone Phase 3 clinical trials for heart failure and type 1 diabetes.

    The analyst projects a $22.1B market opportunity for Sotagliflozin, which is currently under FDA review for heart failure with an action date expected in May 2023.

    In addition, Rahimi highlights LX9211, Lexicon’s (LXRX) candidate for painful diabetic neuropathy, arguing that the Phase 2 asset represents a compelling opportunity for non-dilutive financing.
    Lexicon Pharmaceuticals | 3,170 $
    Avatar
    12.08.22 22:16:48
    Beitrag Nr. 106 ()
    Ab Yahoo Board
    Wyane2 days ago
    it's an old post, but I'd like more people to see it.

    Connecting the dots:

    1) Deepak L. Bhatt recently joined board of Bristol Myers Squibb (BMY) with $46.4B in sales.

    2) Dr. Bhatt served as the principal investigator for many cardiovascular clinical trials including SOTA for HF.

    3) In his publications of SOTA's clinical trials for HF, Dr. Bhatt repeatedly pointed out the best-in-class results of SOTA for HF compared to its cousins of HGLT2 inhibitors.

    4) Dr. Bhatt was the first to highlight the unique benefits of SOTA in preventing MI and stroke, which none of its cousin SGLT2 inhibitor showed.

    5) BMY already knew the potency of LX9211 in animal trials and decided to collaborate with LXRX in the development of LX9211.

    Here is my 2-cents: BMY is eyeing on LXRX for both SOTA for HF and LX9211 for Neuropathic Pain with their blockbuster potentials. If my hunch is right, BMS cannot take control by buying shares in the open market but to negotiate with Raymond Debbane. Knowing Ray, most likely, we won't be disappointed.
    Lexicon Pharmaceuticals | 3,095 €
    Avatar
    12.08.22 16:33:51
    Beitrag Nr. 105 ()
    Sanders setzt Kursziel auf 10 USD, Buy

    Boooom :D
    Lexicon Pharmaceuticals | 3,140 $
    1 Antwort
    Avatar
    30.07.22 12:25:16
    Beitrag Nr. 104 ()
    Antwort auf Beitrag Nr.: 72.066.839 von Charly_2 am 27.07.22 14:08:44
    Zitat von Charly_2: Lift up :)

    Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure Lexicon Pharmaceuticals, Inc.
    Wed, Jul 27, 2022, 07:59 am ET

    https://www.stonkmoon.com/news/LXRX/8c1404e18e47dbc295a0b63f…


    Zuerst werden noch x Millionen Aktien auf den Markt geschmissen zu lächerlichen $2.50 um die die bereits krass genug davon haben zusätzlich zu bereichern D:
    Lexicon Pharmaceuticals | 2,344 €
    Avatar
    28.07.22 23:36:10
    Beitrag Nr. 103 ()
    Antwort auf Beitrag Nr.: 72.077.744 von wohinistmeinGeld am 28.07.22 17:14:02Spassvogel :laugh:
    Lexicon Pharmaceuticals | 2,400 $
    Avatar
    28.07.22 17:14:02
    Beitrag Nr. 102 ()
    Antwort auf Beitrag Nr.: 71.920.827 von Charly_2 am 05.07.22 18:44:17die chance auf 20 Cent ist deutlich höher als auf 20 $, es wird den Weg zur Auflösung wie so viele Biotechs gehen. Die laufenden KEs funktionieren nicht ewig, das ist nix anderes als Kettenbriefe. Alte Schulden mit neuen Schulden zahlen. :laugh:
    Lexicon Pharmaceuticals | 2,500 $
    1 Antwort
    Avatar
    27.07.22 14:08:44
    Beitrag Nr. 101 ()
    Lift up :)

    Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure Lexicon Pharmaceuticals, Inc.
    Wed, Jul 27, 2022, 07:59 am ET

    https://www.stonkmoon.com/news/LXRX/8c1404e18e47dbc295a0b63f…
    Lexicon Pharmaceuticals | 3,100 €
    1 Antwort
    Avatar
    05.07.22 18:44:17
    Beitrag Nr. 100 ()
    Antwort auf Beitrag Nr.: 71.920.761 von Charly_2 am 05.07.22 18:36:31Läuft :D
    https://finance.yahoo.com/quote/LXRX/

    City mit Kursziel $20
    Lexicon Pharmaceuticals | 1,940 $
    2 Antworten
    Avatar
    05.07.22 18:36:31
    Beitrag Nr. 99 ()
    Lexicon Pharmaceuticals | 1,940 $
    3 Antworten
    Avatar
    29.06.22 22:48:56
    Beitrag Nr. 98 ()
    Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy

    https://finance.yahoo.com/news/lexicon-announces-positive-to…

    $2.24 Schlusskurs
    Lexicon Pharmaceuticals | 2,131 €
    • 1
    • 11
     DurchsuchenBeitrag schreiben


    Lexicon Pharmaceuticals Aktie WKN: 936717 ISIN: US5288721047 Symbol: LXRX Typ: Aktie